Astrazeneca Pharma Peer Comparison

NSE: ASTRAZEN | BSE: 506820

₹6,073.00

₹21.50 (0.36%)

As on 27-Oct-2026IST

Market cap

₹15,183 Cr

Revenue (TTM)

₹2,432 Cr

P/E Ratio

89.5

P/B Ratio

16.8

Div. Yield

0.6 %

Edit

	Astrazeneca Pharma	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Market cap (₹ Cr)	15,183	17,896	17,662	16,976	16,614
Revenue (₹ Cr)	2,432	2,287	1,682	2,570	3,330
Net Profit (₹ Cr)	169.62	678.07	273.51	735.15	720.77
Net Margin (%)	6.90	28.10	16.19	26.88	21.60
RoE (%)	20.76	19.73	11.15	19.16	18.93
Price to Earnings	89.51	26.90	59.40	23.09	23.48
Price-To-Book	16.79	4.87	6.58	3.85	4.01

Income Statement (₹ Cr)

	Astrazeneca Pharma	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Operating Revenue	2,432.06	2,287.33	1,682.47	2,569.77	3,329.63
Total Income	2,458.54	2,413.29	1,689.83	2,735.39	3,337.47
Total Expenditure	2,202.20	1,490.75	1,203.91	1,628.14	2,168.88
EBITDA	229.86	796.58	478.55	941.63	1,160.75
Depreciation	17.24	78.10	126.01	57.58	285.40
EBIT	212.62	718.48	352.55	884.05	875.35
Interest	5.72	0.88	52.11	7.69	187.51
Other Income	26.48	125.96	7.37	165.62	7.84
Exceptional Items	-5.13	0.00	12.16	-49.16	-53.14
Profit before Tax	228.25	843.56	319.96	992.82	642.54
Provision for Tax	58.63	165.49	46.45	257.67	-78.23
Profit after Tax	169.62	678.07	273.51	735.15	720.77

	Astrazeneca Pharma	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Shareholder's Funds	872.79	3,586.42	2,591.20	4,202.90	4,144.34
Minority Interest	0.00	-12.71	0.00	0.00	-10.85
Non-Current Liabilities	134.50	28.74	266.35	91.50	758.48
Current Liabilities	981.81	385.94	848.06	627.48	2,681.14
Total Liabilities	2,414.58	4,037.51	3,705.61	4,921.88	7,246.72

	Astrazeneca Pharma	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Non-Current Assets	42.47	1,291.22	2,525.44	770.28	5,578.78
Current Assets	1,739.93	2,585.66	1,109.77	3,803.22	1,800.86
Total Assets	2,414.58	4,037.51	3,705.61	4,921.88	7,246.72
Total Debt*	0.00	0.57	657.97	2.50	2,309.68
Net Current Assets	758.12	2,199.72	261.71	3,175.74	-880.28
Contingent Liabilities	121.23	17.53	160.01	370.49	51.57

	Astrazeneca Pharma	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Cash From Operating Activities	-15.14	523.24	342.18	967.57	537.99
Cash Flow from Investing Activities	18.69	-582.30	-325.92	-561.67	-369.46
Cash from Financing Activities	-91.97	-46.46	13.62	-798.31	-313.53
Net Cash Inflow / Outflow	-88.42	-105.52	29.88	-392.41	-145.00

	Astrazeneca Pharma	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
ROCE (%)	31.24	24.97	11.43	23.39	14.47
ROE (%)	20.76	19.73	11.15	19.16	18.93
ROA (%)	9.67	18.69	7.80	14.95	9.78
EBIT Margin (%)	8.74	31.41	20.95	34.40	26.29
Net Margin (%)	6.90	28.10	16.19	26.88	21.60
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Astrazeneca Pharma	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Revenue Growth (%)	31.10	15.01	27.91	10.69	11.06
EBIT Growth (%)	-12.99	18.45	58.32	24.14	13.71
Net Profit Growth (%)	-7.49	19.61	149.56	-9.09	60.98
EPS Growth (%)	-18.33	17.73	-3.57	14.40	80.38
Book Value Growth (%)	13.51	26.75	9.67	-0.34	36.71

	Astrazeneca Pharma	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Price / Earnings	87.49	26.90	63.02	22.01	21.74
Price / Book Value	16.79	4.87	6.58	3.85	4.01
Dividend Yield (%)	0.59	0.34	0.07	2.02	0.00
EV/EBITDA	64.10	21.20	38.19	14.73	16.24
Market Cap (₹ Cr)	19,398.64	11,439.22	6,819.66	21,592.90	17,980.08

	Astrazeneca Pharma	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Debt to Equity	0.00	0.00	0.07	0.00	0.10
Short term debt to equity ratio	--	0.00	0.16	0.00	0.12
Current Ratio	1.77	6.70	1.31	6.06	0.67
Quick Ratio	0.73	5.59	0.88	5.31	0.49
Interest Coverage	40.90	959.59	7.14	130.11	4.43

	Astrazeneca Pharma	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Debtors to sales (%)	8.79	36.10	30.84	7.07	18.98
Asset Turnover	1.39	0.63	0.48	0.52	0.45
Receivable days	31.88	121.68	113.81	26.06	63.88
Inventory Days	126.03	63.83	84.76	65.95	43.27
Payable days	163.79	108.28	101.94	81.01	151.85
Cash Conversion Cycle	-5.88	77.23	96.62	11.00	-44.70

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.